Serum alpha-1-antitrypsin in patients with malignant tumors occurring in the oral region.
In the present study, we have examined the immunoreactive levels of alpha-1-antitrypsin (AAT) and trypsin-inhibitory capacity (TIC) in the serum of patients with malignant tumors occurring in the oral region. AAT in the MFH group showed significantly high (468 +/- 129 mg/dl, mean +/- SD (n = 4)) as compared to those of other types of sarcoma groups (236 +/- 28 mg/dl, (n = 5)) and healthy controls (226 +/- 36 mg/dl, (n = 75)) (p less than 0.05). Patients with squamous cell carcinoma (SCC) also had increased levels of AAT (269 +/- 35 mg/dl, (n = 18)), but there was no significant difference among other groups including healthy controls. TIC of patients with MFH was higher (2.29 +/- 0.42 IU/ml, (n = 4)) than in the SCC group (1.44 +/- 0.25 IU/ml, (n = 18)), other sarcoma groups 1.21 +/- 0.16 IU/ml, (n = 5)) and controls (1.55 +/- 0.15 IU/ml, (n = 75)). These data suggest that the elevation of AAT and TIC would be helpful in the diagnosis of MFH.
Shirasuna
K
K
1st Department of Oral and Maxillofacial Surgery, Osaka University Faculty of Dentistry, Japan.
Sugiyama
M
M
Watatani
K
K
Morioka
S
S
Hayashido
Y
Y
D000293:Adolescent; D000328:Adult; D000368:Aged; D018219:Histiocytoma, Benign Fibrous / Q000097:blood*; D006801:Humans; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000097:blood*; D000515:alpha 1-Antitrypsin / Q000032:analysis*
D000515:alpha 1-Antitrypsin